BACKGROUND: Fibrosis, as well as myocyte hypertrophy, is the major determinant of prognosis in hypertrophic cardiomyopathy (HCM). Valsartan, an angiotensin II type 1 receptor blocker, may improve myocardial fibrosis in patients with HCM. METHODS AND RESULTS:Twenty-three patients with HCM were randomly divided into 2 groups: 11 patients had valsartan added to conventional treatment (V group) and 12 patients received the conventional therapy (C group). Plasma concentrations of brain natriuretic peptide (BNP), troponin T (TnT), aldosterone (ALDO), procollagen typeI (PIP) and procollagen type III aminoterminal peptide (PIIINP) were measured before and 12 months after this study. Left ventricular wall thickness (LVWT) and ejection fraction (LVEF) were measured by echocardiography. PIP was decreased in the V group (123.2+/-63.1 ng/ml to 102.8+/-37.6, p<0.05), but unchanged in C group (110+/-40.5 ng/ml to 119.9+/-47.4, p=0.22). ALDO concentration was unchanged in the V group (88.5+/-26.2 pg/ml to 91.2+/-26.8, p=0.27), and increased in C group (92.6+/-36.6 ng/ml to 116.0+/-33.3, p<0.05). BNP, PIIINP, and TnT were unchanged by the treatment. There was no significant difference between the 2 groups in either LVWT or LVEF. CONCLUSION:Valsartan suppresses the synthesis of type I collagen in patients with HCM and this was associated with suppression of the increase in ALDO.
RCT Entities:
BACKGROUND:Fibrosis, as well as myocyte hypertrophy, is the major determinant of prognosis in hypertrophic cardiomyopathy (HCM). Valsartan, an angiotensin II type 1 receptor blocker, may improve myocardial fibrosis in patients with HCM. METHODS AND RESULTS: Twenty-three patients with HCM were randomly divided into 2 groups: 11 patients had valsartan added to conventional treatment (V group) and 12 patients received the conventional therapy (C group). Plasma concentrations of brain natriuretic peptide (BNP), troponin T (TnT), aldosterone (ALDO), procollagen type I (PIP) and procollagen type III aminoterminal peptide (PIIINP) were measured before and 12 months after this study. Left ventricular wall thickness (LVWT) and ejection fraction (LVEF) were measured by echocardiography. PIP was decreased in the V group (123.2+/-63.1 ng/ml to 102.8+/-37.6, p<0.05), but unchanged in C group (110+/-40.5 ng/ml to 119.9+/-47.4, p=0.22). ALDO concentration was unchanged in the V group (88.5+/-26.2 pg/ml to 91.2+/-26.8, p=0.27), and increased in C group (92.6+/-36.6 ng/ml to 116.0+/-33.3, p<0.05). BNP, PIIINP, and TnT were unchanged by the treatment. There was no significant difference between the 2 groups in either LVWT or LVEF. CONCLUSION:Valsartan suppresses the synthesis of type I collagen in patients with HCM and this was associated with suppression of the increase in ALDO.
Authors: Carolyn Y Ho; John J V McMurray; Allison L Cirino; Steven D Colan; Sharlene M Day; Akshay S Desai; Steven E Lipshultz; Calum A MacRae; Ling Shi; Scott D Solomon; E John Orav; Eugene Braunwald Journal: Am Heart J Date: 2017-02-16 Impact factor: 4.749
Authors: Anna Axelsson Raja; Ling Shi; Sharlene M Day; Mark Russell; Kenneth Zahka; Harry Lever; Steven D Colan; Renee Margossian; E Kevin Hall; Jason Becker; John Lynn Jefferies; Amit R Patel; Lubna Choudhury; Anne M Murphy; Charles Canter; Richard Bach; Matthew Taylor; Luisa Mestroni; Matthew T Wheeler; Lee Benson; Anjali T Owens; Joseph Rossano; Kimberly Y Lin; Elfriede Pahl; Alexandre C Pereira; Henning Bundgaard; Gregory D Lewis; Jose D Vargas; Allison L Cirino; John J V McMurray; Calum A MacRae; Scott D Solomon; E John Orav; Eugene Braunwald; Carolyn Y Ho Journal: Circ Heart Fail Date: 2019-12-09 Impact factor: 8.790
Authors: Martin Penicka; Pavel Gregor; Roman Kerekes; Dan Marek; Karol Curila; Jiri Krupicka Journal: J Mol Diagn Date: 2008-12-12 Impact factor: 5.568
Authors: Chen-Ching Yuan; Katarzyna Kazmierczak; Jingsheng Liang; Rosemeire Kanashiro-Takeuchi; Thomas C Irving; Aldrin V Gomes; Yihua Wang; Thomas P Burghardt; Danuta Szczesna-Cordary Journal: Cardiovasc Res Date: 2017-08-01 Impact factor: 10.787
Authors: Yuichi J Shimada; Jonathan J Passeri; Aaron L Baggish; Caitlin O'Callaghan; Patricia A Lowry; Gia Yannekis; Suhny Abbara; Brian B Ghoshhajra; Richard D Rothman; Carolyn Y Ho; James L Januzzi; Christine E Seidman; Michael A Fifer Journal: JACC Heart Fail Date: 2013-10-24 Impact factor: 12.035